Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chantal Truffot-Pernot

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Presse Medicale (Paris, France : 1983)|November 7, 2006
[Modern diagnosis of tuberculosis]Chantal Truffot-Pernot, Nicolas Véziris, Wladimir Sougakoff
Presse Medicale (Paris, France : 1983)|November 7, 2006
[Trends in tuberculosis treatment duration]Nicolas Veziris, Alexandra Aubry, Chantal Truffot-Pernot
Antimicrobial Agents and Chemotherapy|September 25, 2003
Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivoNicolas Veziris, Chantal Truffot-Pernot, Alexandra Aubry, et al.
Journal of Clinical Microbiology|October 6, 2006
Performance of the genotype MTBDR line probe assay for detection of resistance to rifampin and isoniazid in strains of Mycobacterium tuberculosis with low- and high-level resistanceFlorence Brossier, Nicolas Veziris, Chantal Truffot-Pernot, et al.
American Journal of Respiratory and Critical Care Medicine|July 11, 2009
Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosisMurad Ibrahim, Chantal Truffot-Pernot, Koen Andries, et al.
Antimicrobial Agents and Chemotherapy|September 7, 2006
Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment durationNacer Lounis, Nicolas Veziris, Aurélie Chauffour, et al.
International Journal of Antimicrobial Agents|February 16, 2007
An intervention programme for the management of multidrug-resistant tuberculosis in FranceMarie-Laure Uffredi, Chantal Truffot-Pernot, Bertrand Dautzenberg, et al.
Antimicrobial Agents and Chemotherapy|December 27, 2005
Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymesAlexandra Aubry, Nicolas Veziris, Emmanuelle Cambau, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 22, 2002
Impacts of interleukin-12 on multiplication of Mycobacterium tuberculosis and Mycobacterium avium complex in miceNacer Lounis, Baohong Ji, Chantal Truffot-Pernot, et al.
American Journal of Respiratory and Critical Care Medicine|October 25, 2008
A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosisNicolas Veziris, Murad Ibrahim, Nacer Lounis, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Presse Medicale (Paris, France : 1983)|November 7, 2006
[Modern diagnosis of tuberculosis]Chantal Truffot-Pernot, Nicolas Véziris, Wladimir Sougakoff
Presse Medicale (Paris, France : 1983)|November 7, 2006
[Trends in tuberculosis treatment duration]Nicolas Veziris, Alexandra Aubry, Chantal Truffot-Pernot
Antimicrobial Agents and Chemotherapy|September 25, 2003
Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivoNicolas Veziris, Chantal Truffot-Pernot, Alexandra Aubry, et al.
Journal of Clinical Microbiology|October 6, 2006
Performance of the genotype MTBDR line probe assay for detection of resistance to rifampin and isoniazid in strains of Mycobacterium tuberculosis with low- and high-level resistanceFlorence Brossier, Nicolas Veziris, Chantal Truffot-Pernot, et al.
American Journal of Respiratory and Critical Care Medicine|July 11, 2009
Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosisMurad Ibrahim, Chantal Truffot-Pernot, Koen Andries, et al.
Antimicrobial Agents and Chemotherapy|September 7, 2006
Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment durationNacer Lounis, Nicolas Veziris, Aurélie Chauffour, et al.
International Journal of Antimicrobial Agents|February 16, 2007
An intervention programme for the management of multidrug-resistant tuberculosis in FranceMarie-Laure Uffredi, Chantal Truffot-Pernot, Bertrand Dautzenberg, et al.
Antimicrobial Agents and Chemotherapy|December 27, 2005
Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymesAlexandra Aubry, Nicolas Veziris, Emmanuelle Cambau, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 22, 2002
Impacts of interleukin-12 on multiplication of Mycobacterium tuberculosis and Mycobacterium avium complex in miceNacer Lounis, Baohong Ji, Chantal Truffot-Pernot, et al.
American Journal of Respiratory and Critical Care Medicine|October 25, 2008
A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosisNicolas Veziris, Murad Ibrahim, Nacer Lounis, et al.
Pageof 2